OR WAIT null SECS
In this interview with Dr. Steven Feldman, the latest findings on tralokinumab-ldrm as an atopic dermatitis treatment were discussed.
At the recent 2023 Fall Clinical Dermatology Conference, several encouraging findings on tralokinumab-ldrm for atopic dermatitis (AD) were presented for attending dermatologists. This data contributes to the research on growing numbers of effective treatments available for patients with AD.
Tralokinumab was approved by the US Food and Drugs Administration (FDA) in December 2021 for adult patients with moderate-to-severe AD.1 It is still the first and only FDA-approved biologic that binds to and inhibits the interleukin (IL)-13 cytokine.
Steven R. Feldman, MD, PhD, a dermatologist and skin pathologist at Wake Forest Baptist Health in North Carolina, spoke with the HCPLive editorial team about some of the new findings presented regarding AD and tralokinumab.
One study had shown that tralokinumab-ldrm provided sustained improvements in AD symptoms across the head and neck regions for up to 4 years, which was the first that Feldman chose to address.
“Now we have developed recently a better understanding of the pathophysiology of the disease and treatments that get at the underlying immunopathogenesis,” Feldman said. “And tralokinumab is one of them. Seeing that it works in the long term is terrific. You might expect the drugs that block the key inflammatory pathway like interleukin-13 and atopic dermatitis should work and work steadily. But there is the concern that biologics can be immunogenic and your body can develop antibodies against them.”
Feldman added that he is pleased to see that tralokinumab does not seem to have a major problem in that area, with patients who continue on with therapy continuing to do well.
For further information on these and other findings on tralokinumab, view the full HCPLive interview segment posted above.
The quotes contained here were edited for clarity.